A Randomized-Controlled Trial to Investigate the Effect of a Novel Music Therapy Application to Reduce Anxiety and Stress
1 other identifier
interventional
75
1 country
1
Brief Summary
This virtual, open-label, three-group, randomized-controlled trial will last six weeks. Participants will be allocated into three groups; the Intervention Group, Spotify Group, and Control Group. All participants will complete a baseline questionnaire before completing their designated regime daily for six weeks. In addition, participants will complete study-specific surveys and validated questionnaires at the end of each week (Week 1, 2, 3, 4, 5 \& 6). The study will include 75 \[participants in total, 25 per group, who all have self-reported concerns around anxiety, stress, or depression. Questionnaires will be used to monitor sleep, cognitive ability, and changes in symptoms of anxiety, depression, and stress. Both study-specific questionnaires and validated questionnaires will be utilized, including the Generalized Anxiety Disorder Assessment (GAD-7), the 9-question Patient Health Questionnaire (PHQ-9), Perceived Stress Scale (PSS), and The World Health Organisation- Five Well-Being Index (WHO-5). Likert scale responses will be examined from baseline to each check-in. Participant responses on product feedback will be presented as % scores.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable anxiety
Started May 2023
Shorter than P25 for not_applicable anxiety
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 29, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 26, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
July 26, 2023
CompletedFirst Submitted
Initial submission to the registry
August 27, 2023
CompletedFirst Posted
Study publicly available on registry
September 1, 2023
CompletedSeptember 1, 2023
August 1, 2023
2 months
August 27, 2023
August 27, 2023
Conditions
Outcome Measures
Primary Outcomes (4)
Change in scores on the Generalized Anxiety Disorder 7-item scale (GAD-7). [Baseline to Week 6]
The GAD-7 is a self-report questionnaire used to assess the severity of generalized anxiety disorder. It consists of seven questions that ask about the frequency and intensity of common symptoms of anxiety over the past two weeks. Each question is scored on a scale from 0 to 3, with the total scores ranging from 0 to 21. The scoring is typically interpreted as follows: 0-4: Minimal anxiety 5-9: Mild anxiety 10-14: Moderate anxiety 15-21: Severe anxiety
6 weeks
Change in scores on the Patient Health Questionnaire-9 (PHQ-9). [Baseline to Week 6]
The PHQ-9 is a self-report questionnaire used to assess the severity of depression symptoms. Each question is scored on a scale from 0 to 3, with the total scores ranging from 0 to 27. The scoring is typically interpreted as follows: 0-4: Minimal depression 5-9: Mild depression 10-14: Moderate depression 15-19: Moderately severe depression 20-27: Severe depression
6 weeks
Change in scores on the Perceived Stress Scale (PSS). [Baseline to Week 6]
The PSS is a widely used self-report questionnaire designed to measure an individual's perception of stress in their life. Higher scores indicate higher perceived stress.
6 weeks
Change in scores on the World Health Organization Well-Being Index (WHO-5). [Baseline to Week 6]
The WHO-5, or World Health Organization Well-Being Index, is a self-reported questionnaire used to measure psychological well-being and mood. Respondents are asked to rate statements on a scale from 0 to 5, where 0 indicates "at no time" and 5 indicates "all of the time." The scores are summed, resulting in a total score that can range from 0 to 25. A total score of 0-13 suggests poor well-being and a higher risk of depression. A total score of 14-17 indicates moderate well-being. A total score of 18-25 suggests good well-being.
6 weeks
Secondary Outcomes (1)
Changes in participant-perceived sleep quality. [Baseline to Week 6]
6 weeks
Study Arms (3)
Intervention Group
EXPERIMENTALParticipants will listen to the SoundMind app for 20 minutes per day, ideally during a moment of stress.
Spotify Group
ACTIVE COMPARATORParticipants will listen to a specified Spotify playlist for 20 minutes per day, ideally during a moment of stress.
Control Group
NO INTERVENTIONThis group will have no tasks prescribed.
Interventions
he SoundMind application uses binaural beats to encourage relaxation, focus, and alertness.
Eligibility Criteria
You may qualify if:
- Male or female
- Between 18-28 years of age
- Self-reported concerns around anxiety, stress, or depression
- Generally healthy - don't live with any uncontrolled chronic disease
- Must have headphones
You may not qualify if:
- Any pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders
- Women who are pregnant, breastfeeding or attempting to become pregnant
- Unwilling to follow the study protocol
- Testing any other product for any other research studies at the same time
- History of epilepsy or seizures
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- SoundMindlead
- Citruslabscollaborator
Study Sites (1)
Citruslabs
Santa Monica, California, 90404, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 27, 2023
First Posted
September 1, 2023
Study Start
May 29, 2023
Primary Completion
July 26, 2023
Study Completion
July 26, 2023
Last Updated
September 1, 2023
Record last verified: 2023-08